Dietary manipulations of polyunsaturated fatty acids, the precursors of endocannabinoids, and its implications in human health and disease

Current Nutrition and Food Science

Volumn 5, Issue 2, 2009, Pages 112-125

  Repossi, G ^a,b   Dain, A ^a   Eynard, A R ^a,b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b CONICET ^*  (Argentina)

Author keywords

2 AG; Anandamide; Arachidonic acid; CB1; CB2; Dietary fatty acids; Endocannabinoids; Essential fatty acids EFA; FAAH; Hyperglycemia; Mental disorders; Obesity; PUFAs; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; INSULIN; LEPTIN; LEPTIN RECEPTOR; POLYUNSATURATED FATTY ACID; RIMONABANT;

ADIPOSE TISSUE; APPETITE; DIETARY INTAKE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FAT INTAKE; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 70350678926     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340109788185571     Document Type: Review

References (131)

1. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-738 (Pubitemid 32323945)
2. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-682
3. Arenos JD, Musty RE, Bucci DJ. Blockade of cannabinoid CB1 receptors alters contextual learning and memory. Eur J Pharmacol 2006; 539: 177-183 (Pubitemid 43783526)
4. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431 (Pubitemid 38063771)
5. Rossato M, Pagano C, Vettor R. The cannabinoid system and male reproductive functions. J Neuroendocrinol 2008; 20: 90-93 (Pubitemid 351552682)
6. Bisogno T, Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 2007; 56: 428-442 (Pubitemid 350026392)
7. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007; 56: 382-392
8. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-632 (Pubitemid 350034979)
9. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008; 170: 397-432. (Pubitemid 352010245)
10. Rademacher D, Patel S, Hopp F, Dean C, Hillard C, Seagard J. Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. Am J Physiol Heart Circ Physiol 2003; 284: 1570-1576 (Pubitemid 36460768)
11. Laezza C, Pisanti S, Crescenzi E, Bifulco M. Anandamide inhibits Cdk2 and activate Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 2006; 580: 6076-6082 (Pubitemid 44666789)
12. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
13. Ullrich O, Merker K, Timm J, Tauber S. Immune control by endocannabinoids - New mechanisms of neuroprotection?. J Neuroimmunol 2007; 184: 127-135 (Pubitemid 46365996)
14. Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 2005; 137: 217-223 (Pubitemid 40502398)
15. Oka S, Yanagimoto Y, Ikeda S, et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2- arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 2005; 280: 18488-18497 (Pubitemid 41389098)
16. Pasqualini ME, Berra MA, Yurawecz MP, Repossi G, Eynard AR. Dietary manipulation of precursor polyunsaturated fatty acids modulates eicosanoid and endocannabinoid synthesis: A potential tool to control tumor development. Curr Nutr Food Sci 2008; 4: 161-175
17. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92: 377-387 (Pubitemid 29249047)
18. Matias I, McPartland JM, Di Marzo V. Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis. J Neurochem 2005; 93: 1141-1156 (Pubitemid 40776569)
19. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene 2006; 370: 64-74.
20. McPartland JM, Norris RW, Kilpatrick CW. Coevolution between cannabinoid receptors and endocannabinoid ligands. Gene 2007; 397: 126-135
21. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613 (Pubitemid 19007296)
22. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564 (Pubitemid 20238806)
23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65. (Pubitemid 23305569)
24. Vettor R, Pagotto U, Pagano C, Pasquali R. Here, there and everywhere: the endocannabinoid system. J Neuroendocrinol 2008; 20: 4-6. (Pubitemid 351552668)
25. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180
26. Tsou K, Mackie K, Sañudo-Peña MC, Walker JM. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999; 93: 969. (Pubitemid 29341643)
27. Alger BE. Retrograde signaling in the regulation of synaptic transmission: Focus on endocannabinoids. Prog Neurobiol 2002; 68: 247-286
28. Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav 2008; 90: 501-511
29. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23. (Pubitemid 43255471)
30. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 2006; 1074: 514-536 (Pubitemid 44532857)
31. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38: 177-188 (Pubitemid 40779571)
32. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
33. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27: 1-4.
34. Begg M, Pacher P, Bátkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-145
35. Rodríguez De Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol 2005; 40: 2-14.
36. De Petrocellis L, Cascio MG, Di MarzoV. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-774 (Pubitemid 38446177)
37. Artman A, Petersen G , Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008; 1781: 200-212
38. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462. (Pubitemid 44394908)
39. Placzek EA, Okamoto Y, Ueda N, Barker EL. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. Neuropharmacology 2008; 55: 1095-1104
40. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handbook Exp Pharmacol 2005; 168: 147-185
41. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prost Leuks Essent Fatty Acids 2002; 66: 101-121.
42. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacol 2008; 54: 1-7. (Pubitemid 350299395)
43. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of phospholipase D generating anandamide and its congeners. J Biol Chem 2004; 279: 5298-5305 (Pubitemid 38220550)
44. Sun X, Dey SK. Aspects of endocannabinoid signaling in periimplantation biology. Mol Cell Endocrinol 2008; 286((1-2 Suppl 1): S3-11.
45. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: Biochemical aspects Pharmacol Biochem Behav 2005; 81: 224-238
46. Sun YX, Tsuboi K, Zhao LY, Okamoto Y, Lambert DM, Ueda N. Involvement of N-acylethanolaminehydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 2005; 1736: 2110-2120 (Pubitemid 41423705)
47. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009; 56(Suppl 1): 244-253
48. Calderón RO, Glocker M, Eynard AR. Lipid and fatty acid composition of different fraction from rat urinary transitional epithelium. Lipids 1998; 33: 1017-1022 (Pubitemid 28516480)
49. Calderon RO, Eynard AR. Fatty acids specifically related to the anisotropic properties of plasma membrane from rat urothelium. Biochim Biophys Acta 2000; 1483: 174-184
50. Calderon RO, Grasso EJ. Symmetric array of the urothelium surface controlled by the lipid lattice composition. Biochem Biophys Res Commun 2006; 339: 642-646
51. Bongiovanni GA, Eynard AR, Calderon RO. Altered lipid profile and changes in uroplakin properties of rat urothelial plasma membrane with diets of different lipid composition. Mol Cell Biochem 2005; 271: 69-75.
52. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding Nacylethanolamines in piglets. Proc Natl Acad Sci USA 2001; 98: 6402-6406 (Pubitemid 32488249)
53. Watanabe S, Doshi M, Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostagland Leukot Essent Fatty Acids 2003; 69: 51-59 (Pubitemid 37421501)
54. Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008; 1781: 52-60.
55. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity 2008; 16: 553-565 (Pubitemid 351328005)
56. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effects of high fat diets. Mol Cell Endocrinol 2008; 286: S66-S78.
57. Carr TP, Jesch ED, Brown AW. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 2008; 28: 641-650.
58. Kennedy G. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond 1953; 140: 578-596
59. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671 (Pubitemid 30205071)
60. Schwartz NW. CNS regulation of food intake. Obesity 2006; 14: 1S-8S.
61. Di Marzo V, Goparaju SK, Wang, L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-885 (Pubitemid 32303781)
62. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-543
63. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006; 2: 318-327
64. Matias I, Cristino L, Di Marzo V. Endocannabinoids: Some like it fat (and sweet too). J Neuroendocrinol 2008; 20: 100-109 (Pubitemid 351552684)
65. Cota D, Marsicano G, Lutz B, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obesity 2003; 27: 289-301. (Pubitemid 36384865)
66. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602
67. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565-572 (Pubitemid 33042646)
68. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-528 (Pubitemid 28555694)
69. Navarro M, Carrera MRA, Fratta W, et al. Functional interaction between opioid and cannabinoid receptors in drug self administration. J Neurosci 2001; 21: 5344-5350 (Pubitemid 32622960)
70. Gómez R , Navarro M , Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 96127. (Pubitemid 35356203)
71. Osei-Hyiaman D, Depetrillo M, Harvey-White J, et al. Cocaine-and amphetaminerelate transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 2005; 81: 273-282 (Pubitemid 41397036)
72. Malcher-Lopes R, Di S, Marcheselli VS, et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006; 26: 6643-6650 (Pubitemid 44318346)
73. Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008; 7: 37.
74. Rodriguez de Fonseca F, Navarro M, Gomez R, et al. An anorexic lipid mediatorregulated by feeding. Nature 2001; 414: 209-212
75. Higgs S, Williams CM, Kirkham TC. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta (9)- tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 2003; 165: 370-377
76. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008; 153: 290-298
77. Bensaid M, Gary-Bobo A, Esclangon JP, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa / fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914
78. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180 (Pubitemid 44271774)
79. Porte D Jr. Central regulation of energy homeostasis the key role of insulin. Diabetes 2006; 55: S155-S60.
80. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-786 (Pubitemid 44739523)
81. Carr TP, Jesch ED, Brown AW. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 2008; 28: 641-650
82. Murphy LL, Munoz RM, Adrian BA, Villanua MA. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998; 5: 432-444
83. Lutz B. Molecular biology of cannabinoid receptors. Prostagland Leukot Essent Fatty Acids 2002; 66: 123-142.
84. Wang H, Xie H, Dey SK. Endocannabinoid signaling directs periimplantation events. AAPS J 2006; 8: E425-E32. (Pubitemid 43958374)
85. Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 2008; 153:182-188
86. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147: S163-S71.
87. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7: E625-E54.
88. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397 (Pubitemid 40523733)
89. Robson P. In: Pertwee RG, Ed. Cannabinoids. Handbook of Experimental Pharmacology Human studies of cannabinoids and medicinal cannabis. Heidelburg: Springer-Verlag 2005; pp. 719-756
90. Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134 (Pubitemid 41653104)
91. Eckel RH. Nonsurgical managment of obesity in adults. N Engl J Med 2008; 358: 1941-1950
92. Samieri C, Féart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 2008; 88: 714-721
93. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obesity Res 2003; 11: 1480-1517 (Pubitemid 41127332)
94. Walton AJ, Snaith ML, Locniskar M, Cumberland AG, Morrow WJ, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 463-466
95. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998; 43: 315-319 (Pubitemid 28137622)
96. Sánchez C, De Ceballos ML, Gómez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 2001; 61: 5784-5789
97. Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 66: 6615-6621 (Pubitemid 44085617)
98. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 6748-6755 (Pubitemid 44085633)
99. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745-755
100. Romero J, Lastres-Becker I, De Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002; 95: 137-152 (Pubitemid 35232132)
101. Gelfand EV, Cannon CP. Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919-1926
102. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. L. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Inv 2005; 115: 1298-1305 (Pubitemid 40629049)
103. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine pelmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003; 9: 756-761 (Pubitemid 36749226)
104. Loftus TM, Jaworsky DE, Frehywot GL, T et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288: 2379-2381 (Pubitemid 30448165)
105. Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci USA 2003; 100: 12624-12629 (Pubitemid 37339949)
106. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557 (Pubitemid 34717699)
107. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843 (Pubitemid 41401077)
108. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060 (Pubitemid 44923642)
109. Jensen MD. Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism. Eur Heart J (Suppl) 2006; 8: B13-B9.
110. Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007; 64: 219-229 (Pubitemid 46155701)
111. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via PI3- kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810-4819 (Pubitemid 350223464)
112. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) oscillation in islet beta-cells via CB1 receptors. Regul Pept 2008; 145: 49-53.
113. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39: 155-162
114. Maccarrone M, Finazzi-Agro A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 2003; 10: 946-955 (Pubitemid 37069472)
115. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity 2007; 15: 837-845 (Pubitemid 46740958)
116. Sharkey KA. Endocannabinoids: biology, mechanism of action and functions. Int J Obes 2006; 30: S4-S6.
117. Abbasi F, Chu JW, Lamendola C, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004; 53: 585-590 (Pubitemid 38270626)
118. Engeli S, Feldpausch M, Gorzelniak KH, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-947 (Pubitemid 36384264)
119. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094 (Pubitemid 38970759)
120. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-356
121. Adibhatla RM, Hatcher JF. Role of lipids in brain injury and diseases. Future Lipidol 2007; 2: 403-422 (Pubitemid 47250149)
122. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2180-2214 (Pubitemid 39486563)
123. Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophrenia Res 2007; 94: 29-36. (Pubitemid 47031599)
124. Vinod KY, Hungund BL. Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci 2006; 27: 540-545
125. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosc Biobehav Rev 2008; 32: 1152-1160
126. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 488-489 (Pubitemid 34851398)
127. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-18625 (Pubitemid 43011275)
128. Nissen S, Nicholls S, Wolski K, et al. Effect of Rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. JAMA 2008; 299: 1547-1560
129. Hughes JR. Smoking and suicide: A brief overview. Drug Alcohol Depend 2008; 98: 169-178.
130. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut (Review) 2001; 48: 859-867
131. Pazos MR, Núñez ES, Benito B, Tolón MR, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005; 81: 239-247